[ Price : $8.95]
Two Alston & Bird attorneys give a comprehensive analysis of the new CDER compliance program for pre-license and preapproval inspe...[ Price : $8.95]
Media reports suggest FDA commissioner Marty Makarys time at FDA may be limited due to White House tension over his management of ...[ Price : $8.95]
CBER acting director Katherine Szarama discusses an expansive vision for the biologics center during remarks at the Food and Drug ...[ Price : $8.95]
Pharmaceutical advertising experts react to FDAs dramatically altered enforcement approach toward prescription drug promotion sinc...[ Price : $8.95]
Sanofi asks FDA to remove its Type 1 diabetes therapy Tzield from the agencys National Priority Voucher review program following a...[ Price : $8.95]
A Brookings Institution health economist voices support for FDAs revisions to a guidance on questions and answers about biosimilar...[ Price : $8.95]
Five Hogan Lovells attorneys say a House Appropriations Committee report could prohibit FDA from accepting drug IND trial data fro...[ Price : $8.95]
FDA releases the form FDA-483 with 10 observations from a 2025 inspection at Indias Somerset Therapeutics Private Limited.